To determine which of the downregulated pathways upon TSA treatment functions downstream of HDAC activity to exert oncogenic or tumor suppressive effects in ERMS, we utilized pathway-specific small molecule inhibitors. The gene discussed is HDAC9; the disease is neoplasm.